monday is earnings day. they need to exceed the estimated eps, IMO and guide towards good news, possibily with a small contract announcement not just promises that they are working on things. I think the market is waiting for them to work towards their annual eps guidance and the Q1 is the first step.
on lighter than avg volume. IMO, the 3 biggest holdbacks on the stock are that it is not well known, moves on big contract announcements and foreign stock. The second item could overide the other two, but in the mean time, not may are aware of SPCB as evidenced by 150k shares avg volume. They need to start mentioning the breakdown of recurring revenue too in their earning releases to show that they just don't make money on the implementation of the contract, but recurring revenue too. thoughts?
the increase in backlog in the scenario you mentioned is due to the record amount of orders received. And...as you know, these are not widgets that can be produced by the millions, these are highly specialized machines that take a long time to produce, ship and install and make sure they are running correctly before it is considered revenue. As the CEO stated in this release, there are multi units and multi million dollar sales in two major industries that the company is working on. In no way is the problem an issue of working thru their backlog. It just takes time and depends on the customer timing as well.
i've been a holder since before the debacle last year and am still in the red. i got the annual report and was reading thru it and noticed that the director comp for 2014 for the top 5 people was over $600k in cash and stock. While unfortunately this is common, i thought the amount was unreasonably high. Geesh, this is .08 per share !! Any comments? Still a holder and see all good news ahead. Great earnings report the other day too.
Took a quick look at ctix and sounds promising, but will watch it for a while. It is very early for a 300M market value. It's still on the pinks it looked like. I took a few swings at bio tech and pharma companies recently and all but ISIS didn't work out. Rode isis from 8 to 60. But others are many times hyped up and then go flat. GL.